Chapter 006

Adrenergic Agonists

Yaping Tu, Michael T. Piascik, and Peter W. Abel

CITED REFERENCES

  1. Arnold A, McAuliff JP, Colella DF, et al: The β2-receptor mediated glycogenolytic responses to catecholamines in the dog. Arch Int Pharmacodyn Ther 176:451-457, 1968. PUBMED Abstract
  2. Benoit PW: Microscarring in skeletal muscle after repeated exposures to lidocaine with epinephrine. J Oral Surg 36:530-533, 1978. PUBMED Abstract
  3. Braun H: Über einige neue örtliche Änasthetica (Stovain, Alypin, Novacain). Deutsche Med Wochens 31:1667-1671, 1905.
  4. Bylund DB, Eikenberg DC, Hieble JP, et al: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136, 1994. PUBMED Abstract
  5. Calhoun NR: Dry socket and other postoperative complications. Dent Clin North Am 15:337-348, 1971. PUBMED Abstract
  6. Campbell RL: Cardiovascular effects of epinephrine overdose: case report. Anesth Prog 24:190-193, 1977. PUBMED Abstract
  7. Cannell H, Walters H, Beckett AH, et al: Circulating levels of lignocaine after perioral injections. Br Dent J 138:87-93, 1975. PUBMED Abstract
  8. Drugs used in extrapyramidal movement disorders. In: Drug evaluations annual 1995, Chicago, 1995, American Medical Association.
  9. Dybing E, Nelson SD, Mitchell JR, et al: Oxidation of α-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. Mol Pharmacol 12:911-920, 1976.
  10. Eisenhofer G, Kopin IJ, Goldstein DS: Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331-349, 2004. PUBMED Abstract
  11. Foster CA, Aston SJ: Propranolol-epinephrine interaction: a potential disaster. Plast Reconstr Surg 72:74-78, 1983. PUBMED Abstract
  12. Fuller RW, Roush BW: Substrate-selective and tissue-selective inhibition of monoamine oxidase. Arch Int Pharmacodyn Ther 198:270-276, 1972. PUBMED Abstract
  13. Funakoshi Y, Iwai S, Kaneda H, et al: Hemodynamic effects of locally applied epinephrine used with various general anesthetic techniques. J Oral Surg 35:713-718, 1977. PUBMED Abstract
  14. Gerke DC, Ahrns B, Frewin DB, et al: The effect of local anaesthetics on the neural uptake of catecholamines in isolated arteries—a histochemical study. Aust J Exp Biol Med Sci 54:601-604, 1976.
  15. Gingrich JA, Caron MG: Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16:299-321, 1993. PUBMED Abstract
  16. Goldberg LI, Kohli JD: Peripheral dopamine receptors: classification based on potency series and specific antagonism. Trends Pharmacol Sci 4:64-66, 1983.
  17. Greenhill LL: Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am 15:1-27, 1992. PUBMED Abstract
  18. Guanfacine for hypertension. Med Lett Drugs Ther 29:49-50, 1987. PUBMED Abstract
  19. Hanbauer I: Regulation of tyrosine hydroxylase in carotid body. Adv Biochem Psychopharmacol 16:275-280, 1977. PUBMED Abstract
  20. Hieble JP, Bylund DB, Clarke DE, et al: International Union of Pharmacology. X. Recommendation for nomenclature of α1-adrenoceptors: consensus update. Pharmacol Rev 47:267-270, 1995. PUBMED Abstract
  21. Jastak JT, Yagiela JA: Vasoconstrictors and local anesthesia: a review and rationale for use. J Am Dent Assoc 107:623-630, 1983. PUBMED Abstract
  22. Kaplan EL, editor: Cardiovascular disease in dental practice, Dallas, 1986, American Heart Association.
  23. Katz RL, Epstein RA: The interaction of anesthetic agents and adrenergic drugs to produce cardiac arrhythmias. Anesthesiology 29:763-784, 1968. PUBMED Abstract
  24. Keesling GR, Hinds EC: Optimal concentration of epinephrine in lidocaine solutions. J Am Dent Assoc 66:337-340, 1963. PUBMED Abstract
  25. Kernan WN, Viscoli CM, Brass LM, et al: Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343:1826-1832, 2000. PUBMED Abstract
  26. Knoll-Kohler E, Frie A, Becker J, et al: Changes in plasma epinephrine concentration after dental infiltration anesthesia with different doses of epinephrine. J Dent Res 68:1098-1101, 1989.
  27. Kopin IJ: Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppl 41:57-67, 1994. PUBMED Abstract
  28. Kopin IJ: Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37:333-364, 1985. PUBMED Abstract
  29. Lal H, Fielding S: Clonidine in the treatment of narcotic addiction. Trends Pharmacol Sci 4:70-71, 1983.
  30. Lauschke A, Teichgräber UKM, Frei U, et al: “Low-dose” dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 69:1669-1674, 2006. PUBMED Abstract
  31. Leier CV: Current status of non-digitalis positive inotropic drugs. Am J Cardiol 69:120G-129G, 1992. PUBMED Abstract
  32. Lipp M, Dick W, Daublander M, et al: Exogenous and endogenous plasma levels of epinephrine during dental treatment under local anesthesia. Reg Anesth 18:6-12, 1993. PUBMED Abstract
  33. Lomasney JW, Cotecchia S, Lefkowitz RT, et al: Molecular biology of α-adrenergic receptors: implications for further classification and structure-function relationships. Biochem Biophys Acta 1095:127-139, 1991.
  34. Malta E, McPherson GA, Raper C: Selective β1-adrenoceptor agonists—fact or fiction? Trends Pharmacol Sci 6:400-403, 1985.
  35. Management of dental problems in patients with cardiovascular disease. Council on Dental Therapeutics, American Dental Association and American Heart Association joint report. J Am Dent Assoc 68:333-342, 1964.
  36. Michel MC, Kenny B, Schwinn DA: Classification of α1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 352:1-10, 1995. PUBMED Abstract
  37. Minneman KP, Theroux TL, Hollinger S, et al: Selectivity of agonists for cloned α1-adrenergic receptor subtypes. Mol Pharmacol 46:929-936, 1994. PUBMED Abstract
  38. Murphy MB, Elliott WJ: Dopamine and dopamine receptor agonists in cardiovascular therapy. Crit Care Med 18:S14-S18, 1990. PUBMED Abstract
  39. Nelson HS: β-Adrenergic bronchodilators, N Engl J Med 333:499-507, 1995. PUBMED Abstract
  40. Piascik MT, Perez DM: α1-Adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403-410, 2001. PUBMED Abstract
  41. Priori SG, Napolitano C, Schwartz PJ: Cardiac receptor activation and arrhythmogenesis. Eur Heart J 14(Suppl E):20-26, 1993. PUBMED Abstract
  42. Rabe KF, Jorres R, Nowark D, et al: Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 147:1436-1441, 1993. PUBMED Abstract
  43. Ruffolo RR Jr, Nichols AJ, Stadel JM, et al: Pharmacologic and therapeutic applications of α2-adrenoceptor subtypes. Annu Rev Pharmacol Toxicol 33:243-279, 1993. PUBMED Abstract
  44. Schenarts PJ, Sagraves SG, Bard MR, et al: Low-dose dopamine: a physiologically based review. Curr Surg 63:219-225, 2006. PUBMED Abstract
  45. Sibley DR, Monsma FJ Jr: Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69, 1992. PUBMED Abstract
  46. Strader CD, Candetore MR, Hill WS, et al: Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J Biol Chem 264:13572-13578, 1989. PUBMED Abstract
  47. Troullos ES, Goldstein DS, Hargreaves KM, et al: Plasma epinephrine levels and cardiovascular response to high administered doses of epinephrine contained in local anesthesia. Anesth Prog 34:10-13, 1987.
  48. Troullos ES, Hargreaves KM, Goldstein DS, et al: Epinephrine suppresses stress-induced increases in plasma immunoreactive β-endorphin in humans. J Clin Endocrinol Metab 69:546-551, 1989.
  49. Verrill PJ: Adverse reactions to local anaesthetics and vasoconstrictor drugs. Practitioner 214:380-387, 1975.
  50. Wilhelmi BJ, Blackwell SJ, Miller JH, et al: Do not use epinephrine in digital blocks: myth or truth? Plast Reconstr Surg 107:393-397, 2001. PUBMED Abstract
  51. Yagiela JA: Local anesthetics. Anesth Prog 38:128-141, 1991. PUBMED Abstract

GENERAL REFERENCES

  1. Bader JD, Bonito AJ, Shugars DA: Cardiovascular effects of epinephrine in hypertensive dental patients. Summary, Evidence Report/Technology Assessment: Number 48, AHRQ Publication No. 02-E006, Rockville, MD, 2002, Agency for Healthcare Research and Quality. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.71824. Accessed January 10, 2009.
  2. Cooper JR, Bloom FE, Roth RH: The biochemical basis of neuropharmacology, ed 8, New York, 2003, Oxford University Press.
  3. Jowett NI, Cabot LB: Patients with cardiac disease: considerations for the dental practitioner, Br Dent J 189:297-302, 2000. PUBMED Abstract
  4. Nestler EJ, Hyman SE, Malenka RC: Molecular neuropharmacology: a foundation for clinical neuroscience, New York, 2001, McGraw-Hill.
  5. Ruffolo RR Jr, Hieble JP: Alpha-adrenoceptors, Pharmacol Ther 61:1-64, 1994. PUBMED Abstract
  6. Wong J: Adjuncts to local anesthesia: separating fact from fiction, J Can Dent Assoc 67:391-397, 2001. PUBMED Abstract